NASDAQ: ESPR
Esperion Therapeutics Inc Stock

$1.17-0.03 (-2.5%)
Updated Jun 13, 2025
ESPR Price
$1.17
Fair Value Price
N/A
Market Cap
$231.89M
52 Week Low
$0.69
52 Week High
$3.94
P/E
-1.46x
P/B
-0.54x
P/S
1.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$259.57M
Earnings
-$153.22M
Gross Margin
65.3%
Operating Margin
-34.12%
Profit Margin
-59%
Debt to Equity
-1.76
Operating Cash Flow
-$100M
Beta
0.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ESPR Overview

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ESPR's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
ESPR
Ranked
#57 of 59

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important ESPR news, forecast changes, insider trades & much more!

ESPR News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ESPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ESPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ESPR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ESPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ESPR due diligence checks available for Premium users.

Valuation

ESPR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.46x
Industry
-23.1x
Market
31.36x

ESPR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-0.54x
Industry
2.26x

ESPR's financial health

Profit margin

Revenue
$65.0M
Net Income
-$40.5M
Profit Margin
-62.2%
ESPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ESPR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$324.0M
Liabilities
$750.2M
Debt to equity
-1.76
ESPR's short-term assets ($318.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ESPR's long-term liabilities ($479.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ESPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ESPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$22.6M
Investing
$0.0
Financing
-$7.5M
ESPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ESPR vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ESPRD$231.89M-2.50%-1.46x-0.54x
LFCRD$249.18M-1.46%-4.55x111.79x
CGCD$274.08M-3.27%-0.37x0.79x
OGIC$187.37M-4.76%31.82x0.67x
TKNOC$292.86M-5.68%-11.66x3.73x

Esperion Therapeutics Stock FAQ

What is Esperion Therapeutics's quote symbol?

(NASDAQ: ESPR) Esperion Therapeutics trades on the NASDAQ under the ticker symbol ESPR. Esperion Therapeutics stock quotes can also be displayed as NASDAQ: ESPR.

If you're new to stock investing, here's how to buy Esperion Therapeutics stock.

What is the 52 week high and low for Esperion Therapeutics (NASDAQ: ESPR)?

(NASDAQ: ESPR) Esperion Therapeutics's 52-week high was $3.94, and its 52-week low was $0.69. It is currently -70.3% from its 52-week high and 68.83% from its 52-week low.

How much is Esperion Therapeutics stock worth today?

(NASDAQ: ESPR) Esperion Therapeutics currently has 198,199,462 outstanding shares. With Esperion Therapeutics stock trading at $1.17 per share, the total value of Esperion Therapeutics stock (market capitalization) is $231.89M.

Esperion Therapeutics stock was originally listed at a price of $14.50 in Jun 26, 2013. If you had invested in Esperion Therapeutics stock at $14.50, your return over the last 11 years would have been -91.93%, for an annualized return of -20.45% (not including any dividends or dividend reinvestments).

How much is Esperion Therapeutics's stock price per share?

(NASDAQ: ESPR) Esperion Therapeutics stock price per share is $1.17 today (as of Jun 13, 2025).

What is Esperion Therapeutics's Market Cap?

(NASDAQ: ESPR) Esperion Therapeutics's market cap is $231.89M, as of Jun 15, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Esperion Therapeutics's market cap is calculated by multiplying ESPR's current stock price of $1.17 by ESPR's total outstanding shares of 198,199,462.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.